| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/17476348.2016.1261016 |
| P698 | PubMed publication ID | 27842444 |
| P50 | author | Cecilia Chaparro | Q96650257 |
| Shaf Baloch Keshavjee | Q19518807 | ||
| P2860 | cites work | Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. | Q51999514 |
| Mycobacterium abscessus infections in lung transplant recipients: the international experience. | Q53244839 | ||
| Infectious complications of lung transplantation. Impact of cystic fibrosis. | Q54205174 | ||
| Efficacy of aerosolized tobramycin in patients with cystic fibrosis. | Q54237890 | ||
| Cystic fibrosis | Q55881299 | ||
| The Risk of Cancer among Patients with Cystic Fibrosis | Q56779992 | ||
| Development of the new lung allocation system in the United States | Q56899327 | ||
| Infection withBurkholderia cepaciaComplex Genomovars in Patients with Cystic Fibrosis: Virulent Transmissible Strains of Genomovar III Can ReplaceBurkholderia multivorans | Q57265587 | ||
| Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis | Q57913762 | ||
| Voriconazole Prophylaxis in Lung Transplant Recipients | Q59230762 | ||
| Cystic Fibrosis Pulmonary Guidelines | Q22306311 | ||
| Risk Factors for Death of Patients with Cystic Fibrosis Awaiting Lung Transplantation | Q22306317 | ||
| US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis | Q26775974 | ||
| Cable pili and the 22-kilodalton adhesin are required for Burkholderia cenocepacia binding to and transmigration across the squamous epithelium | Q30437827 | ||
| Burkholderia and emerging pathogens in cystic fibrosis | Q30998871 | ||
| Double-lung transplantation for cystic fibrosis. The Cystic Fibrosis Transplant Study Group | Q33221763 | ||
| Lung transplantation in older patients with cystic fibrosis: analysis of UNOS data | Q33406762 | ||
| Timing of referral for lung transplantation for cystic fibrosis: overemphasis on FEV1 may adversely affect overall survival | Q33543150 | ||
| Survival benefit of lung transplant for cystic fibrosis since lung allocation score implementation. | Q33738670 | ||
| Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections | Q33786154 | ||
| Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study | Q33801253 | ||
| The changing microbial epidemiology in cystic fibrosis | Q33825634 | ||
| Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a patient with cystic fibrosis | Q33971419 | ||
| Taxonomy and identification of the Burkholderia cepacia complex | Q33973532 | ||
| Living-donor lobar lung transplantation experience: intermediate results | Q34063649 | ||
| Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients | Q34150943 | ||
| Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation | Q34157044 | ||
| Lung transplantation for cystic fibrosis and bronchiectasis | Q34355141 | ||
| Gender gap in cystic fibrosis mortality | Q34425312 | ||
| The impact of pretransplant mechanical ventilation on short- and long-term survival after lung transplantation | Q34598811 | ||
| Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. | Q34610291 | ||
| Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in Scandinavia | Q34982469 | ||
| Non-tuberculous mycobacteria in cystic fibrosis | Q35532270 | ||
| Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project | Q35535262 | ||
| Risk factors for chronic kidney disease in adults with cystic fibrosis. | Q35682983 | ||
| The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre | Q35739322 | ||
| Regulation of membrane chloride currents in rat bile duct epithelial cells | Q35824120 | ||
| High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients | Q36019684 | ||
| Clinical importance of cystic fibrosis-related diabetes | Q36033722 | ||
| Risk of post-lung transplant renal dysfunction in adults with cystic fibrosis. | Q36163519 | ||
| Cystic fibrosis since 1938. | Q36242757 | ||
| Combined lung and liver transplantation: the United States experience | Q36325550 | ||
| Lung transplantation for cystic fibrosis: current concepts and one center's experience | Q36785504 | ||
| Survival effect of lung transplantation among patients with cystic fibrosis | Q36848757 | ||
| Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov. | Q36886857 | ||
| Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel | Q36944748 | ||
| Outcomes of lung transplantation for cystic fibrosis in a large UK cohort. | Q37166949 | ||
| Predictive utility of the 6-minute walk distance on survival in patients awaiting lung transplantation | Q37200997 | ||
| Nasal and sinus disease in cystic fibrosis | Q37241314 | ||
| Infections relevant to lung transplantation | Q37365025 | ||
| Burkholderia cepacia complex: impact on the cystic fibrosis lung lesion | Q37598713 | ||
| Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. | Q37633119 | ||
| Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single-center experience. | Q37784583 | ||
| Changing epidemiology and clinical issues arising in an ageing cystic fibrosis population | Q37809636 | ||
| Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation. | Q38007023 | ||
| Ageing in cystic fibrosis and long-term survival | Q38089996 | ||
| Mold infections in lung transplant recipients | Q38118956 | ||
| Respiratory infections in patients with cystic fibrosis undergoing lung transplantation | Q38181712 | ||
| A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. | Q38236174 | ||
| Predictors of quality of life and adjustment after lung transplantation | Q38472520 | ||
| Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis | Q38603508 | ||
| Complications of gastroesophageal reflux in patients with cystic fibrosis | Q39564003 | ||
| Cystic fibrosis in adults. 75 cases and a review of 232 cases in the literature | Q39879907 | ||
| Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. | Q39972823 | ||
| The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Report--2015; Focus Theme: Early Graft Failure | Q40445072 | ||
| Gastroesophageal reflux disease in lung transplant recipients | Q40574117 | ||
| Hepatobiliary disease in cystic fibrosis | Q40639766 | ||
| Psychological functioning and quality of life in lung transplant candidates and recipients | Q40753239 | ||
| Clinical and demographic factors associated with post-lung transplantation survival in individuals with cystic fibrosis. | Q40823069 | ||
| Effect of infection with transmissible strains of Pseudomonas aeruginosa on lung transplantation outcomes in patients with cystic fibrosis | Q41629855 | ||
| Infections in patients with cystic fibrosis following lung transplantation. | Q41648945 | ||
| A contemporary survival analysis of individuals with cystic fibrosis: a cohort study | Q41662756 | ||
| Management of Scedosporium apiospermum in a pre- and post-lung transplant patient with cystic fibrosis | Q41860921 | ||
| Pretransplant Aspergillus colonization of cystic fibrosis patients and the incidence of post-lung transplant invasive aspergillosis. | Q42238065 | ||
| Use of lung transplantation survival models to refine patient selection in cystic fibrosis. | Q42647223 | ||
| Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States | Q43684856 | ||
| Determinants of mortality from cystic fibrosis in Canada, 1970-1989. | Q43698922 | ||
| Diabetes mellitus and cystic fibrosis: comparison of clinical parameters in patients treated with insulin versus oral glucose-lowering agents | Q43763355 | ||
| Nontuberculous Mycobacteria in Adult Patients with Cystic Fibrosis | Q44146527 | ||
| Increasing nontuberculous mycobacteria infection in cystic fibrosis | Q44189223 | ||
| Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis | Q44324883 | ||
| Bacterial sinusitis can be a focus for initial lung colonisation and chronic lung infection in patients with cystic fibrosis | Q44462802 | ||
| Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985-2005. | Q44528304 | ||
| Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial | Q44602962 | ||
| Epidemiology of liver disease in cystic fibrosis: a longitudinal study | Q45175701 | ||
| Increased risk of colorectal neoplasia in adult patients with cystic fibrosis: a matched case-control study. | Q45403827 | ||
| Extracorporeal membrane oxygenation as bridge to lung transplantation. | Q45860789 | ||
| P. aeruginosa in the paranasal sinuses and transplanted lungs have similar adaptive mutations as isolates from chronically infected CF lungs | Q46061294 | ||
| Lung and heart-lung transplantation in patients with end-stage cystic fibrosis: the Stanford experience | Q46590060 | ||
| Outcome of heart-lung and bilateral sequential lung transplantation for cystic fibrosis: a UK national study | Q47787863 | ||
| Gastroesophageal reflux in patients with cystic fibrosis | Q49049673 | ||
| Survival of cystic fibrosis patients undergoing liver and liver-lung transplantations | Q50112176 | ||
| GI complications after lung transplantation in patients with cystic fibrosis | Q50174126 | ||
| Timing and priorities for cystic fibrosis patients candidates to lung transplantation. | Q50856330 | ||
| The effect of lung transplantation on health-related quality of life: a longitudinal study. | Q51098925 | ||
| Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. | Q51193602 | ||
| Bridge to lung transplantation with the novel pumpless interventional lung assist device NovaLung. | Q51253690 | ||
| The CF-ABLE score: a novel clinical prediction rule for prognosis in patients with cystic fibrosis. | Q51298027 | ||
| Risk factors for voriconazole hepatotoxicity at 12 weeks in lung transplant recipients. | Q51385199 | ||
| Pre-transplant mechanical ventilation and outcome in patients with cystic fibrosis. | Q51678199 | ||
| Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. | Q51697432 | ||
| Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. | Q51699145 | ||
| Noninvasive ventilation in cystic fibrosis patients with acute or chronic respiratory failure. | Q51726178 | ||
| Association of lung perfusion disparity and mortality in patients with cystic fibrosis awaiting lung transplantation. | Q51728251 | ||
| P433 | issue | 12 | |
| P921 | main subject | cystic fibrosis | Q178194 |
| lung transplant | Q1637912 | ||
| P304 | page(s) | 1269-1280 | |
| P577 | publication date | 2016-11-15 | |
| P1433 | published in | Expert Review of Respiratory Medicine | Q15754583 |
| P1476 | title | Lung transplantation for cystic fibrosis: an update | |
| P478 | volume | 10 |
| Q40054770 | Burkholderia cenocepacia Infections in Cystic Fibrosis Patients: Drug Resistance and Therapeutic Approaches |
| Q90461396 | Cryptides Identified in Human Apolipoprotein B as New Weapons to Fight Antibiotic Resistance in Cystic Fibrosis Disease |
| Q57300566 | Molecular basis of cystic fibrosis: from bench to bedside |
| Q61451210 | Mortality Due to Cystic Fibrosis over a 36-Year Period in Spain: Time Trends and Geographic Variations |
| Q47808441 | Pediatric lung transplantation and end of life care in cystic fibrosis: Barriers and successful strategies. |
| Q90387464 | The future of cystic fibrosis care: a global perspective |
Search more.